Notice of Claimed Investigational

Figure 7.1 Information supplied to the CVM in support of a Notice of Claimed Investigational Exemption (NCIE) for an Investigational New Animal Drug (INAD).

Once a drug is judged ready to be studied in humans, a Notice of Claimed Investigational Exemption for a New... 

In the United States, the federal FD C Act and its amendments require that a manufacturer demonstrate the safety and efficacy of a new drug prior to introducing it into interstate commerce. The requirements are clearly spelled out in the Notice of Claimed Investigational Exemption for a New Drug (IND) and the NDA. 

Notice of Claim, penalty, and settlement agreements are the FMCSA s processes for fining a carrier and can be initiated after any of the investigative interventions. 

Final Order Failure to comply with final agency order. Automatic waiver of any reduction in the original claim found to be valid, and immediate restoration to the full amount assessed in the Claim Letter or Notice of Investigation. 

In interviews and informal discussions with company regulatory personnel and clinical researchers, OTA learned that many people involved in the process believe at least some reviewers in ODER use the application not complete notice to manage workloads. These sources claim that ODER staff can always find some additional information is necessary, so the agency can manipulate the starting date of its statutory time limit. To investigate this claim is beyond the scope of the study, but the very existence of this rather widespread belief suggests it is almost impossible to separate out delays in the approval process due to companies inadequate applications from those due to the regulatory process. 

---